You’ve probably heard that there’s an updated COVID-19 vaccine on the market, and maybe you’ve already gotten your updated booster. But there are new kinds of vaccines in development that go beyond just tweaking protection to better cover circulating variants.
In one promising development, researchers adapted the decades-old MMR (measles, mumps, and rubella) vaccine into one covering measles, mumps, and multiple variants of SARS-CoV-2—and, rather than a shot, they delivered that experimental vaccine via a nasal spray.
Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, joins Ira to talk about the approach, the advantages of nasal vaccines, and other vaccines on the horizon that make use of the mRNA technology that was the focus of this year’s Nobel Prize in Physiology or Medicine. Topol hopes that the mRNA approach will be widely applicable to a range of diseases and conditions—from conventional pathogens to cancers and autoimmune disorders.
To stay updated on all-things-science, sign up for Science Friday's newsletters. Transcripts for each segment will be available the week after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
